NovoCure Files 8-K/A Amendment
Ticker: NVCR · Form: 8-K/A · Filed: Dec 17, 2024 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K/A |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $700,000, $120,000, $1 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, corporate-governance, executive-appointments
Related Tickers: NVCR
TL;DR
NovoCure filed an amendment to its 8-K, updating info on exec changes and compensation.
AI Summary
NovoCure Limited filed an 8-K/A on December 17, 2024, amending its previous filing from August 30, 2024. The amendment pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. The filing also includes financial statements and exhibits.
Why It Matters
This amendment provides updated information regarding changes in NovoCure's leadership and executive compensation, which can be crucial for investors assessing corporate governance and financial health.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report and primarily concerns corporate governance and executive appointments, not a significant financial event.
Key Players & Entities
- NovoCure Limited (company) — Registrant
- Jersey (location) — Jurisdiction of incorporation
- August 30, 2024 (date) — Date of earliest event reported
- December 17, 2024 (date) — Filing date
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A filing amends information related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What was the original report date that this 8-K/A filing amends?
The 8-K/A filing amends the report dated August 30, 2024, which was the date of the earliest event reported.
When was this 8-K/A filing submitted to the SEC?
This 8-K/A filing was submitted to the SEC on December 17, 2024.
What is NovoCure Limited's principal executive office address?
NovoCure Limited's principal executive offices are located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
What is the SIC code for NovoCure Limited?
NovoCure Limited's Standard Industrial Classification (SIC) code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 1,485 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2024-12-16 19:54:38
Key Financial Figures
- $700,000 — is agreement, Mr. Danziger will receive $700,000 per year through December 31, 2025 and
- $120,000 — per year through December 31, 2025 and $120,000 per year through the End Date (the "Bas
- $1 — li Shekels at the exchange rate of 4NIS/$1, subject to adjustment by the Company's
Filing Documents
- nvcr-20240830.htm (8-K/A) — 33KB
- ceoemploymentagreementex101.htm (EX-10.1) — 109KB
- senioradvisortoceoemployme.htm (EX-10.2) — 140KB
- 0001645113-24-000036.txt ( ) — 459KB
- nvcr-20240830.xsd (EX-101.SCH) — 2KB
- nvcr-20240830_lab.xml (EX-101.LAB) — 21KB
- nvcr-20240830_pre.xml (EX-101.PRE) — 12KB
- nvcr-20240830_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Employment Agreement between Ashley Cordova and Novocure GmbH effective as of January 1, 2025 10.2 Employment Agreement between Asaf Danziger and Novocure (Israel) Ltd. effective as of January 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: December 11, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer